Posted on 15/03/2010 in Pharmaceutical Company Product News Pfizer has published results from two new clinical trails gauging the efficacy of its drug Sutent in treating breast cancer when used in conjunction with chemotherapy.
The two phase III studies evaluated the treatment in combination with docetaxel and capecitabine regimens, with both trials failing to meet their primary endpoint of improving progression-free survival rates.
This is despite Sutent having already been approved as a treatment for gastrointestinal stromal tumours, with more than 82,000 patients having used the drug to date.
Despite the disappointing results from the latest trials, Pfizer nevertheless expressed confidence that the studies themselves have helped the firm to better understand the "complex biology" of the illness.
Dr Mace Rothenberg, senior vice-president of clinical development and medical affairs for Pfizer's oncology business unit, said: "Pfizer Oncology is committed to the rigorous evaluation of investigational therapies in breast cancer, which despite recent advancements, continues to claim far too many lives each year."
This comes after the company cancelled another phase III cancer trial this month after concluding that figitumumab, the drug in question, would be unable to meet its primary endpoint.Other news stories from 15/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
